The nation of Zimbabwe has turned down a major US health deal worth $367m (£272m) spanning five years due to the United States' demand for sensitive biological samples.
This rejection was revealed following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesperson later clarified that the US was requesting genetic material for scientific study and commercial gain but refused to share the benefits from future treatments.
"We must now begin the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further dialogue to reach a deal acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Implications
This rejection follows a similar case in neighbouring Kenya, where a court halted a similar deal with the US following concerns were filed about the security of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
According to reports, 16 nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no equivalent guarantee of access to any medical innovations – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the end products would be accessible to our people should a future health crisis emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one deals were upending structures previously set up via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This framework is intended to ensure that when a country contributes its information, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to continued dialogue with our US partners on how future co-operation could be arranged in a way that respects the independence and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks should continue given that a large portion of the nation's Aids initiatives were funded by international support.
"Where technical issues exist, including those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," the group said.
The halted deal emphasises the ongoing challenges between receiving much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.